The kinase inhibitor cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2

Luke R.E. Harrison , Christopher J. Ottley , D. Graham Pearson , Roger J. Griffin , Stephen R. Wedge , M. Eileen Dolan , David R. Newell , Michael J. Tilby

-Cyclohexylmethylguanine (NU2058) was developed as an inhibitor of CDK2 and was previously shown to potentiate cisplatin cytotoxicity . The aim of this study was to investigate the mechanism of cisplatin potentiation by NU2058.

Mots clés: CDK; DMSO; DMF; HPLC; ICP-MS; IR; Rb; Cisplatin; Melphalan; Potentiation; Kinase inhibitor; NU2058

Luke R.E. Harrison, Christopher J. Ottley, D. Graham Pearson, Roger J. Griffin, Stephen R. Wedge, et al.. The kinase inhibitor cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Biochemical Pharmacology, 2009, 77 (10), pp.1586. ⟨10.1016/j.bcp.2009.02.018⟩. ⟨hal-00493497⟩